Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics announced it will present updated Phase 1/2 clinical data for BEAM-302, its lead genetic disease program for Alpha-1 Antitrypsin Deficiency, at the ERS Congress in September. The company describes the upcoming dataset as robust, reinforcing the therapy's potential to address both lung and liver disease by correcting the underlying PiZ mutation.
Key figures
- Drug Name
- BEAM-302
- Phase Of Trial
- Phase 1/2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.